Industry News

Anthem and Cigna. The suit charges a merge would increase concentration in the industry and harm competition in Tennessee and across the country, ultimately impacting services and prices."/>
Tennessee, Georgia join with feds to block Anthem's purchase of Cigna [Chattanooga Times Free Press, Tenn.]
Aetna Inc. and Anthem Inc., with Attorney General Loretta Lynch criticizing the deals as anti-competitive and being pursued "at the expense of consumers across America." Anti-trust lawsuits were filed in District of Columbia federal court against both deals. Anthem proposed to acquire Bloomfield-based Cigna for $54 billion and Hartford-based Aetna sought Humana Inc. for..."/>
U.S. Suing To Block Aetna-Humana and Anthem-Cigna Mergers [The Hartford Courant]
Humana. LOUISVILLE, Ky.---- On July 21, 2016, after the market close, Humana Inc. was informed by the U.S. Department of Defense that it has been awarded the contract for the TRICARE East Region."/>
Humana Awarded Department of Defense TRICARE East Region Contract
Insmed Incorporated concerning possible violations of federal securities laws between March 18, 2013 and June 8, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 13, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Insmed Incorporated and Reminds Investors With Losses to Contact the Firm
TransEnterix, Inc. announced today that it plans to release second quarter 2016 financial and operating results before the market opens on Friday, August 5, 2016. Todd M. Pope, President and Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 8:30 am Eastern Time the same day. The call will be concurrently webcast."/>
TransEnterix Schedules Second Quarter 2016 Financial and Operating Results Conference Call for August 5, 2016
Gilead Sciences, Inc. today announced that two Phase 3 b switch studies evaluating Odefsey ® for the treatment of HIV-1 infection met their primary objectives. The ongoing studies were designed to explore the efficacy and safety of Odefsey among virologically suppressed adult patients switching from the tenofovir disoproxil fumarate- based regimens Complera ® or Atripla ®. Odefsey combines Gilead’ s emtricitabine and tenofovir alafenamide with..."/>
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter 2016 after the close of trading on Thursday, August 4, 2016. The Company’ s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call..."/>
Corindus Vascular Robotics to Report Second Quarter 2016 Financial Results on August 4, 2016
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase additional shares of its common stock. All of the securities in the offering are to be sold by ContraFect. Piper Jaffray& Co. is acting as sole..."/>
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
Retrophin, Inc. today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.. A replay of the call will be available from 7:30 p.m. ET, August 4, 2016 to 11:59 p.m. ET, August 11, 2016."/>
Retrophin to Report Second Quarter 2016 Financial Results
Surgery Partners, Inc., a leading healthcare services company, today announced that the Company will release its second quarter 2016 results after the market close on Tuesday, August 9, 2016, to be followed by a conference call on Wednesday, August 10 at 8:30 a.m... The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can..."/>
Surgery Partners, Inc. Announces Second Quarter 2016 Earnings Release Date and Conference Call Details
Puma Biotechnology, Inc., a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma’ s investigational drug PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab in women with early stage HER2-positive breast cancer. The ExteNET trial randomized..."/>
Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Emergent BioSolutions Inc. will host a conference call on Thursday, August 4, 2016 at 5:00 pm to discuss the financial results for the second quarter of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.. This conference call can be accessed live by telephone or through Emergent’ s website:. Pre-registering for the live call will expedite access and minimize..."/>
Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016
Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Heat. Heat intends to grant the underwriters a 45- day option to purchase up to an additional 15 percent of the securities to be sold."/>
Heat Biologics Announces Proposed Public Offering of Common Stock
Puma Biotechnology, Inc., a biopharmaceutical company, has submitted a New Drug Application to the U.S. Food and Drug Administration for its lead product candidate PB272 for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab- based therapy. “We are very pleased to announce this important regulatory milestone,” said Alan H. Auerbach, Chief Executive Officer and..."/>
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Orexigen Therapeutics, Inc. will announce corporate and financial results for the second quarter 2016 on Thursday, August 4 th after the market closes. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 2:00 p.m. Pacific Time. The live call may be accessed by phone by calling 771-4371 or 585-4405, participant code 42982061.."/>
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016
TESARO, Inc. will announce its second-quarter 2016 financial results on Thursday, August 4, 2016, after the close of the U.S. financial markets. TESARO’ s senior management will host a conference call and live audio webcast at 4:15 p.m. ET on August 4, 2016 to discuss the Company’ s operating results in greater detail, as well as the status of its development programs and the VARUBI ® launch.. The quarterly earnings call will be available via phone and..."/>
TESARO to Announce Second-Quarter 2016 Financial Results on August 4, 2016
Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4: 30 pm ET on the same day to discuss..."/>
Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016
Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., today announced that it will host a conference call at 4:30 p.m. ET on Thursday, August 4, 2016, to discuss its financial and operating results for the second quarter of 2016.. To access the live conference call via telephone, please dial 1-866-498-8390 or 1-678-509-7599 and provide passcode 47799009. A live audio webcast of the call also will be available on the homepage of the..."/>
Lantheus Holdings to Host Second Quarter 2016 Earnings Conference Call on August 4, 2016 at 4:30 p.m. Eastern Time
Second Sight Medical Products, Inc., the developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, today announced positive five-year outcomes associated with patients using the Argus ® II Retinal Prosthesis System. The Argus II captures images on an eyeglass-mounted..."/>
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
BioMarin Pharmaceutical Inc. announced today that interim results of an open-label, Phase 1/ 2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia will be presented at the XXXII International Congress of the World Federation of Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. BioMarin management to hold conference call and webcast to discuss the data on Wednesday, July 27, at 4:05pm ET.."/>
BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th
Impax Laboratories, Inc., a specialty pharmaceutical company, today announced that it has filled a key executive leadership role, appointing Douglas S. Boothe as president of the Generics Division effective August 1, 2016. Boothe will join the Company's Executive Committee, reporting directly to the Chief Executive Officer and be responsible for all aspects of the generic business. "The addition of this seasoned industry executive will..."/>
Impax Names Douglas S. Boothe President of Generics Division
OncoGenex Pharmaceuticals, Inc. announced today that it will report its second quarter 2016 financial results on Thursday, August 4, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update. To access the webcast, log on to the Investor Relations page of the OncoGenex..."/>
OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016
OncoGenex Pharmaceuticals, Inc. announced today that it will report its second quarter 2016 financial results on Thursday, August 4, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update. To access the webcast, log on to the Investor Relations page of the..."/>
OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials742 Articles
Consumer Discretionary671 Articles
Information Technology661 Articles
Industrials488 Articles
Health Care380 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.